-
Breaking New Ground in Oligometastatic Kidney Cancer | Prof. Liru He’s Team Reports Sunitinib Plus SBRT Strategy in Cell Reports Medicine
The treatment landscape for renal cell carcinoma (RCC), one of the most common malignancies of the urinary system, continues to evolve rapidly, with targeted therapy combined with immunotherapy now established as a standard first-line approach for advanced and metastatic disease. However, for patients with oligometastatic RCC, a standardized treatment strategy has yet to be established.
-
19th CUA Genitourinary Oncology Conference | Professor Baojun Wang: Breaking Through the Bottlenecks in Prostate Cancer Treatment—Balancing Clinical Innovation with Standardized Care
The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, under the theme “Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation.” The meeting brought together leading experts in urologic oncology from across China to examine the current challenges facing the field and explore future directions for clinical research…
-
19th CUA Genitourinary Oncology Conference | Professor Xuesong Li: Advancing the UTUC Subspecialty Through High-Quality Research to Address Key Clinical Challenges
The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was held in Beijing on July 3–4, 2026, bringing together leading experts from across China under the theme “Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation.” The meeting provided a platform for discussing new directions in urologic oncology research and clinical practice.
-
19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology
The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was successfully held in Beijing on July 3–4, 2026. Centered on the theme “Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation,” the meeting featured in-depth discussions on precision oncology, early screening and prevention of prostate cancer, and the development of a robust domestic clinical research ecosystem,…
-
Blood Advances Study | Director Zhihui Li’s Team Demonstrates Survival Benefit of HSCT in Advanced ENKTCL, Paving the Way for Precision Risk Stratification
Extranodal NK/T-cell lymphoma (ENKTCL) is a rare, highly aggressive lymphoid malignancy closely associated with Epstein–Barr virus (EBV) infection. Patients with advanced-stage or relapsed/refractory (R/R) disease continue to face poor outcomes, making effective treatment a longstanding clinical challenge. Recently, Director Zhihui Li and colleagues from Beijing GoBroad Boren Hospital published a study in Blood Advances entitled…
-
BCJ Publishes Chinese CMML Cohort Study | Simpler Variables, More Accurate Risk Stratification? Investigators Discuss Why the BLAST Model Outperformed CPSS
Chronic myelomonocytic leukemia (CMML) is a highly heterogeneous myeloid malignancy in which early identification of high-risk patients is critical for timely referral to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recently, a collaborative team led by Professor Zheng Ge of Zhongda Hospital, Southeast University, and Professor Shuqian Xu of Qilu Hospital, Shandong University, published a study…
-
CSCO 10th Hematologic Malignancies Congress | Director Yajing Zhang: Moving Beyond “Target-Centric” Thinking to Redefine Lifelong Management of Hematologic Malignancies Through a Systems-Based Approach
From July 10–12, 2026, the 10th Hematologic Malignancies Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin, China. Over the past decade, the meeting has grown into one of China’s premier academic forums for hematologic oncology. This year’s congress not only celebrated ten years of scientific achievement but also marked an…
-
BOC 2026 | Spotlight on Homegrown Innovation: Professor Zhitao Ying Interprets the Lymphoma Highlights from the Annual Progress in Clinical Oncology in China 2025
From July 3–4, 2026, the 2026 Best of Clinical Oncology (BOC) Academic Conference & Best of CSCO 2026 China was held in Hohhot, Inner Mongolia. This year’s meeting marked the transformation of the former “BOA/BOC” conference into BOC, reflecting a significant shift in academic focus—from primarily introducing and interpreting international advances to highlighting China’s own…
Connecting Medical Expertise through Media